 | |
 | |
| Clinical data | |
|---|---|
| Other names | β-Methoxy-2C-D; 4-Methyl-2,5,β-trimethoxyphenethylamine; β-MeO-2C-D |
| Routes of administration | Oral[1] |
| Drug class | Serotonergic psychedelic;Hallucinogen |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | 8–16 hours[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C12H19NO3 |
| Molar mass | 225.288 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
BOD, also known as4-methyl-2,5,β-trimethoxyphenethylamine or asβ-methoxy-2C-D, is apsychedelic drug of thephenethylamine,2C, andBOx families.[1] It is the β-methoxyderivative of2C-D.[1] The drug is takenorally.[1]
In his bookPiHKAL (Phenethylamines I Have Known and Loved),Alexander Shulgin lists BOD's dose range as 15 to 25 mgorally and itsduration as 8 to 16 hours.[1] Its reported effects include mildopen-eye and moderateclosed-eye visual changes, enhancement ofconversation and sense ofhumor, and unpleasant physical effects such asnausea andlethargy.[1]
Very little data exists about the pharmacological properties, metabolism, and toxicity of BOD.[1]
Thechemical synthesis of BOD has been described.[1]
Analogues of BOD includeBOHD (β-hydroxy-2C-D) andBOB (β-methoxy-2C-B), among others.[1]
BOB was first described in thescientific literature byAlexander Shulgin,Peyton Jacob III, andDarrell Lemaire in 1985.[2] Subsequently, it was described in greater detail by Shulgin in his 1991 bookPiHKAL (Phenethylamines I Have Known and Loved).[1]
This substance is a Class A drug in theDrugs controlled by the UK Misuse of Drugs Act.[3]
BOD is unscheduled in theUnited States, but purchase, sale, or possession for human consumption could be prosecuted under theFederal Analogue Act.[4]
